.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 3,957,982

« Back to Dashboard

Claims for Patent: 3,957,982

Title: Method for contraception by the application of combination-type sequential preparations
Abstract:Method of contraception in which an estrogen and a progestagen are orally administered daily for 21 days, the first 4-6 days at a low contraceptively effective daily dose, the next 4-6 days at a daily estrogen dose 1-2 times and a daily progestrogen dose 1-1.5 times that of the first 4-6 days, and for the next 9-11 days at a daily estrogen dose from that of the first 4-6 days to that of the next 4-6 days and a daily progestogen dose higher than either prior daily dose, up to 3 times that of the initial dose, followed by 7 days without hormone administration.
Inventor(s): Lachnit-Fixson; Ursula (Berlin, DT), Pitchford; Alan G. (High Hurstwood, near Uckfield, EN)
Assignee: Schering Aktiengesellschaft (Berlin & Bergkamen, DT)
Application Number:05/535,575
Patent Claims: 1. A method of contraception which comprises administering for 21 successive days to a female of child-bearing age a combination of an estrogen and a progestogen, for the first 4-6 days in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 0.020-0.050 mg. of 17.alpha.-ethinylestradiol and in progestogenic activity to 0.050-0.125 mg. of d-norgestrel; for the next 4-6 days, at an estrogen daily dosage from 1-2 times the initial daily low dosage and at a progestogen daily dosage of from 1-1.5 times the dosage of the first 4-6 days; and for the next 9-11 days, at a daily estrogen dosage of from the initial daily dosage to the subsequent daily dosage and at a progestogen daily dosage higher than the previous daily dosages of up to 3 times that of the first daily dosage and corresponding in progestogenic activity to 0.100-0.250 mg. of d-norgestrel, followed by about 7 days without progestogen and estrogen administration.

2. A method according to claim 1 wherein the estrogen and progestogen are administered orally.

3. A method according to claim 1 wherein the estrogen and progestogen are administered in admixture.

4. A method according to claim 1 wherein the first combination of estrogen and progestogen is administered for 6 days, the second combination of estrogen and progestogen is administered for 5 days, the third combination of estrogen and progestogen is administered for 10 days and a placebo is administered for 7 days.

5. A method according to claim 1 wherein in at least one of the stages the estrogen is 17.alpha.-ethinylestradiol.

6. A method according to claim 5 wherein the estrogen in all three stages is 17.alpha.-ethinylestradiol.

7. A method according to claim 1 wherein in at least one of the stages the progestogen is d-norgestrel.

8. A method according to claim 7 wherein the progestogen in all three stages is d-norgestrel.

9. A method according to claim 1 wherein in at least one of the stages the progestogen is cyproterone acetate or 17.alpha.-ethinyl-19-nortestosterone acetate.

10. A method according to claim 1 wherein in all three stages the progestogen is d-norgestrel and the estrogen is 17.alpha.-ethinyl-19-nortestosterone acetate and they are administered orally in admixture.

11. A method according to claim 9 wherein 0.040 - 0.090 mg., 0.050 - 0.125 mg. and 0.100 - 0.250 mg., respectively, of d-norgestrel and 0.020 - 0.050 mg., 0.030 - 0.050 mg. and 0.025 - 0.050 mg., respectively, of 17.alpha.-ethinylestradiol are administered in the first, second and third stages.

12. The three-stage oral contraceptive composition comprising 21 separate dosage units, adapted for successive daily oral ingestion, consisting essentially of:

as the first stage, 4-6 dosage units containing, in admixture with a pharmaceutically acceptable carrier, a combination of an estrogen and a progestogen at low but contraceptively effective respective dosages corresponding in activity to 0.020-0.050 mg. of 17.alpha.-ethinyl-estradiol and in progestogenic activity to 0.050-0.125 mg. of d-norgestrel followed by, as the second stage, 4-6 dosage units containing, in admixture with a pharmaceutically acceptable carrier, a combination of an estrogen at a dosage from the same to twice the dosage of the first stage, and a progestogen at a dosage from 1-1.5 times the dosage of the first stage, followed by, as the third stage, 9-11 dosage units containing, in admixture with pharmaceutically acceptable carrier, a combination of an estrogen at a dosage from that of the first stage to that of the second stage, and a progestogen at a higher dosage than the first and second stages up to three times that of the first stage and corresponding in progestogenic activity to 0.100-0.250 mg. of d-norgestrel, optionally followed by, as the fourth stage, 7 dosage units free of estrogen and progestogen.

13. A composition according to claim 12 wherein the dosage units are in the form of tablets.

14. A composition according to claim 12 wherein in at least one of the stages the estrogen is 17.alpha.-ethinylestradiol.

15. A composition according to claim 14 wherein the estrogen in all three stages is 17.alpha.-ethinylestradiol.

16. A composition according to claim 12 wherein in at least one of the stages the progestogen is d-norgestrel.

17. A composition according to claim 16 wherein the progestogen in all three stages is d-norgestrel.

18. A composition according to claim 12 wherein in at least one of the stages the progestogen is cyproterone acetate or 17.alpha.-ethinyl-19-nortestosterone acetate.

19. A composition according to claim 12 wherein in all three stages the progestogen is d-norgestrel and the estrogen is 17.alpha.-ethinyl-19-nortestosterone acetate.

20. A composition according to claim 19 wherein 0.040 - 0.090 mg., 0.050 - 0.125 mg. and 0.100 - 0.250 mg., respectively, of d-norgestrel and 0.020 - 0.050 mg., 0.030 - 0.050 mg. and 0.025 - 0.050 mg., respectively, of 17.alpha.-ethinylestradiol and in the first, second and third stages.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc